Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18055298 | 1.00 | AAK1 (0.35) | AAK1CA1CA2CA7MMP13 | |
| SCHEMBL20902060 | 0.88 | CTSS (0.39) | AAK1CA1CA2CA7CTSS | |
| SCHEMBL4145893 | 0.85 | AAK1 (0.37) | AAK1CA1CA2CA7MMP13 | |
| SCHEMBL21258087 | 0.82 | AAK1 (0.36) | AAK1CA1CA2CA7MMP13 | |
| SCHEMBL17618251 | 0.82 | AAK1 (0.36) | AAK1CA1CA2CA7MMP13 | |
| SCHEMBL13682813 | 0.81 | CA12 (0.38) | AAK1CA1CA2CA7MMP13 | |
| SCHEMBL7020025 | 0.81 | CA12 (0.38) | AAK1CA1CA2CA7MMP13 | |
| SCHEMBL23428809 | 0.80 | CA1 (0.33) | AAK1CA1CA2CA7 | |
| SCHEMBL2160514 | 0.80 | CA1 (0.33) | AAK1CA1CA2CA7MMP13 | |
| SCHEMBL59435 | 0.80 | CA1 (0.33) | AAK1CA1CA2CA7MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | AAK1 3664/4885CA1 3162/4885CA2 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.